Literature DB >> 19149477

Immune-mediated adverse drug reactions.

Jack Uetrecht1.   

Abstract

Many adverse drug reactions are mediated by the immune system. This can be because the therapeutic effect of the drug targets the immune system. For example, immunosuppressive drugs increase the risk of infections. It is paradoxical that some immunosuppressive drugs can lead to autoimmune reactions. Another mechanism by which drugs can cause an adverse reaction involves an idiosyncratic response to the drug such as an immune-mediated skin rash. These idiosyncratic drug reactions (IDRs) are difficult to study because of the paucity of valid animal models and their unpredictable nature. Therefore, much of our mechanistic knowledge of IDRs is based on inferences from the clinical characteristics of IDRs rather than on controlled mechanistic studies. In general, IDRs are associated with a delay between starting the drug and the onset of the adverse reaction, and the typical delay is different for different types of IDRs. In contrast, on rechallenge, there is usually a rapid onset of the adverse reaction, which is characteristic of an amnestic immune response. The absence of such a rapid response is usually considered evidence that an IDR is not immune-mediated; yet, there are immune-mediated IDRs that do not have an amnestic response. One possible reason for the lack of an amnestic response is if the IDR has a strong autoimmune component leading to deletion of autoimmune memory cells when the drug is withdrawn. Another interesting characteristic of IDRs is that there are many drugs that can cause different types of IDRs in different patients. A possible explanation is that although the immune response is induced by a drug, it is directed against an autoantigen, and interindividual differences in the immune repertoire determine which autoantigen and target organ are affected. Although testing these hypotheses represents a difficult challenge, the importance of these adverse reactions makes it a high priority.

Entities:  

Mesh:

Year:  2009        PMID: 19149477     DOI: 10.1021/tx800389u

Source DB:  PubMed          Journal:  Chem Res Toxicol        ISSN: 0893-228X            Impact factor:   3.739


  24 in total

1.  Strategies for discovering and derisking covalent, irreversible enzyme inhibitors.

Authors:  Douglas S Johnson; Eranthie Weerapana; Benjamin F Cravatt
Journal:  Future Med Chem       Date:  2010-06       Impact factor: 3.808

Review 2.  Mechanisms of drug toxicity and relevance to pharmaceutical development.

Authors:  F Peter Guengerich
Journal:  Drug Metab Pharmacokinet       Date:  2010-10-22       Impact factor: 3.614

Review 3.  The resurgence of covalent drugs.

Authors:  Juswinder Singh; Russell C Petter; Thomas A Baillie; Adrian Whitty
Journal:  Nat Rev Drug Discov       Date:  2011-04       Impact factor: 84.694

4.  A Case of Thiopurine-Induced Acute Myocarditis in a Patient with Ulcerative Colitis.

Authors:  Anastasiya Latushko; Leyla J Ghazi
Journal:  Dig Dis Sci       Date:  2016-10-20       Impact factor: 3.199

5.  Covalent protein binding and tissue distribution of houttuynin in rats after intravenous administration of sodium houttuyfonate.

Authors:  Zhi-peng Deng; Da-fang Zhong; Jian Meng; Xiao-yan Chen
Journal:  Acta Pharmacol Sin       Date:  2012-03-05       Impact factor: 6.150

6.  Predictive value of the lymphocyte toxicity assay in the diagnosis of drug hypersensitivity syndrome.

Authors:  Abdelbaset A Elzagallaai; Zahra Jahedmotlagh; Blanca R Del Pozzo-Magaña; Sandra R Knowles; Asuri N Prasad; Neil H Shear; Michael J Rieder; Gideon Koren
Journal:  Mol Diagn Ther       Date:  2010-10-01       Impact factor: 4.074

7.  Identification of protein targets of reactive metabolites of tienilic acid in human hepatocytes.

Authors:  Yakov M Koen; Diganta Sarma; Todd D Williams; Nadezhda A Galeva; R Scott Obach; Robert P Hanzlik
Journal:  Chem Res Toxicol       Date:  2012-04-10       Impact factor: 3.739

8.  Stronger association of drug-induced progressive multifocal leukoencephalopathy (PML) with biological immunomodulating agents.

Authors:  Carlo Piccinni; Chiara Sacripanti; Elisabetta Poluzzi; Domenico Motola; Lara Magro; Ugo Moretti; Anita Conforti; Nicola Montanaro
Journal:  Eur J Clin Pharmacol       Date:  2009-10-17       Impact factor: 2.953

9.  Protein targets of thioacetamide metabolites in rat hepatocytes.

Authors:  Yakov M Koen; Diganta Sarma; Heather Hajovsky; Nadezhda A Galeva; Todd D Williams; Jeffrey L Staudinger; Robert P Hanzlik
Journal:  Chem Res Toxicol       Date:  2013-03-20       Impact factor: 3.739

Review 10.  Idiosyncratic adverse drug reactions: current concepts.

Authors:  Jack Uetrecht; Dean J Naisbitt
Journal:  Pharmacol Rev       Date:  2013-03-08       Impact factor: 25.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.